
A big rise in the number of people with type 2 diabetes in recent years does not fully explain the soaring costs.
Researchers pointed to marked increases in use of newer and more expensive therapies like rosiglitazone, as well as increasing use of insulin, which have been marketed aggressively by the drug companies.
The researchers say that the NHS needs to get a hold on the situation.